Form 4: RYTM CFO Sells Shares Under Pre-Set Plan

Rhythm Pharmaceuticals' CFO, Hunter C. Smith, sold common stock totaling 28,088 shares in August 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, Inc. (RYTM), engaged in transactions involving the company's common stock.
• On August 12, 2025, Smith exercised options to acquire 24,611 shares of common stock at an exercise price of $6.88 per share.
• Concurrently, on August 12, 2025, Smith sold 24,611 shares of common stock at a weighted average price of $96.3322 per share, with prices ranging from $96.00 to $96.63.
• On August 13, 2025, Smith exercised options to acquire an additional 3,477 shares of common stock at an exercise price of $6.88 per share.
• On the same day, August 13, 2025, Smith sold 3,477 shares of common stock at a price of $96.00 per share.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on February 28, 2025.
• Following these transactions, Smith's direct beneficial ownership of Rhythm Pharmaceuticals common stock is 116,915 shares.
• The stock options exercised were fully vested.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that it is under a Rule 10b5-1 plan mitigates concerns about negative insider sentiment. The significant profit from option exercise also reflects positively on the company's stock performance over time.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than a reaction to negative company news.
• The significant difference between the option exercise price ($6.88) and the sale price (around $96) indicates substantial personal gain for the CFO, which can be a positive signal of long-term value creation for early option holders.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This is an insider transaction filing, which typically does not provide industry context. The sale under a 10b5-1 plan suggests it is a personal financial planning event rather than a reflection of specific industry trends.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a pre-arranged plan, could lead to minor short-term market speculation, but the Rule 10b5-1 plan generally mitigates concerns about negative signals. The substantial profit realized by the CFO from options exercised at a much lower price than the sale price could be seen as a positive indicator of the company's stock performance over the vesting period.

Key Dates

Recommendation

This is a routine Form 4 detailing insider stock transactions under a pre-arranged Rule 10b5-1 plan. Such transactions are typically for personal financial management and do not inherently signal new positive or negative information about the company's operational performance or future prospects. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' stance based solely on this filing.

Keywords

Rhythm Pharmaceuticals, RYTM, Hunter C. Smith, CFO, Insider Trading, Form 4, Stock Options, Rule 10b5-1 Plan, Share Sale, Beneficial Ownership